Effects of duloxetine on painful physical symptoms associated with depression.

Department of Psychitry adn the Department of Pharmacology adn toxicology, Indiana Unibersity School of Medicine, Indianapolis, USA.
Psychosomatics (Impact Factor: 1.67). 03/2004; 45(1):17-28. DOI: 10.1176/appi.psy.45.1.17
Source: PubMed

ABSTRACT Painful physical symptoms are common features of major depressive disorder and may be the presenting complaints in primary care settings. The effect of the dual serotonin (5-HT) and norepinephrine reuptake inhibitor duloxetine on emotional and painful physical symptoms in outpatients with major depressive disorder was evaluated in three randomized, double-blind, placebo-controlled trials. The trials' primary objective was to evaluate the effect of duloxetine on mood, and subjects were not enrolled on the basis of presence, type, or severity of pain. However, the pain-relieving effects of duloxetine were evaluated by a priori defined analyses of results from a visual analogue scale and the Somatic Symptom Inventory. Compared with placebo, duloxetine was associated with significant reduction in pain severity. The authors concluded that duloxetine reduces the painful physical symptoms of depression.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Unexplained painful physical symptoms are commonly reported by depressed patients. The evidence suggests that dual-action antidepressants are potent in relieving pain in depression. However, a direct comparison of the effects of selective serotonergic and selective noradrenergic antidepressants on painful symptoms has not been investigated so far. Sixty patients who participated in the Genome-based Therapeutic Drugs for Depression study with a diagnosis of moderate or severe episodes of depression according to the International Classification of Diseases, 10th Revision, and the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, criteria were involved. All the participants were randomly allocated to receive nortriptyline or escitalopram. The severity of depression was measured using the Montgomery-Åsberg Depression Rating Scale, the Hamilton Depression Rating Scale and the Beck Depression Inventory at weeks 0, 2, 4, 6 and 8. The intensity of pain was measured on the Visual Analog Scale at the same points of the study. At "week 0," 83.3% of the patients later randomized to treatment with escitalopram and 86.7% of those treated with nortriptyline reported at least one painful symptom. A significant decrease of pain intensity was observed after 2 weeks of treatment. The two groups did not differ in degree of pain reduction at weeks 2, 4, 6 and 8 in comparison to baseline values. A 50% reduction in pain intensity preceded the 50% reduction of depression severity. The intensity of pain at "week 0" did not differ in remitted or nonremitted patients at week 8. Both selective serotonergic and selective noradrenergic antidepressants are equally effective in alleviations of painful physical symptoms of depression. The presence of painful symptoms before the onset of treatment did not determine the final response. Copyright © 2014 Elsevier Inc. All rights reserved.
    General Hospital Psychiatry 10/2014; · 2.90 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the efficacy and safety of duloxetine hydrochloride in the treatment of patients affected by chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Thirty-eight CP/CPPS patients completed the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) and International Index of Erectile Function-Erectile Function-5 (IIEF-5) questionnaires, uroflowmetry, and evaluation of psychologic status using Hamilton Anxiety Scale (HAM-A) and Hamilton Depression Scale (HAM-D). Patients were randomly assigned to 2 treatments groups. Treatment in group 1 consisted of a simultaneous oral administration of tamsulosin (0.4 mg/d, 60 mg/d), saw palmetto (320 mg/d), and duloxetine (60 mg/d). Treatment in group 2 consisted of tamsulosin (0.4 mg/d) and saw palmetto (320 mg/d). NIH-CPSI and IIEF-5 questionnaires, uroflowmetry, and evaluation of the psychological status were repeated at 16 weeks of follow-up. At 16 weeks, a significant improvement in NIH-CPSI pain subscore, NIH-CPSI quality of life subscore, and NIH-CPSI total score were observed in group 1 patients compared with those in group 2 (P <.01, respectively), together with a significant improvement in HAM-A and HAM-D scores (P <.01, respectively). Patients in group 2 showed a significant improvement in NIH-CPSI total score, in the urinary symptoms subscore, and in the HAM-A total score. No significant differences were observed in IIEF-5 scores in the 2 groups. Maximum flow rate significantly increased in both groups. In group 1, 20% of patients stopped the study due to adverse effects. The use of duloxetine in a multimodal treatment with an α-blocker medication and a saw palmetto extract allowed better results in controlling clinical symptoms, psychologic status and quality of life patients affected by CP/CPPS.
    Urology 11/2013; · 2.13 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Los pacientes con trastornos depresivos frecuentemente manifiestan quejas somáticas como, por ejemplo, dolor. La mejoría en la percepción del dolor que se produce en pacientes con síntomas depresivos tratados con antidepresivos puede deberse a una mejoría en la depresión. Varias publicaciones indican que la actividad antinociceptiva de los antidepresivos es independiente de la mejoría del estado de ánimo y que está en relación con el efecto de estos fármacos en vías noradrenérgicas y serotoninérgicas ascendentes y descendentes.En modelos animales, sustancias que inhiben selectivamente la recaptación de noradrenalina disminuyen la percepción del dolor; compuestos que inhiben de manera selectiva la recaptación de serotonina no tienen ese efecto pero potencian el efecto antinociceptivo de las que inhiben la recaptación de noradrenalina.Disminuyendo la percepción del dolor se contribuye a mejorar los síntomas depresivos que pudieran coexistir. Una mejoría en los síntomas depresivos que pudieran magnificar la percepción del dolor contribuiría a disminuir esta última; el efecto de algunos fármacos en el sistema límbico puede conducir a mejorar tanto la percepción del dolor como el estado de ánimo.Duloxetina posee acción dual como inhibidor de la recaptación de serotonina y noradrenalina. Investigaciones recientes señalan que no es possible discernir entre el efecto analgésico y antidepresivo de duloxetina. Otros estudios evidencian que el efecto de duloxetina en la percepción del dolor es independiente del efecto antidepresivo. La evolución del caso presentado parece apoyar la hipótesis de que duloxetina contribuye de manera independiente a la mejoría de ambos tipos de síntomas.
    Psiquiatría Biológica. 01/2008; 15(1):23-26.